Grundlæggende statistik
| CIK | 1087294 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cumberland Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 5, 2025 |
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date NASHVILLE, Tenn. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 5, 2025 (August 5, 2025) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 6, 2025 |
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 NASHVILLE, Tenn. (Tuesday, May 06, 2025) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 6, 2025 (May 6, 2025) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorpor |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 28, 2025 (April 28, 2025) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 19, 2025 (March 19, 2025) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| March 19, 2025 |
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference Ifetroban demonstrated significant 5. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement þ Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 7, 2025 |
Effective January 1, 2025 Chris Bitterman 605 Press Place, Apt. 107 Nashville, TN 37208 Re: Employment of Chris Bitterman, Vice President Sales & Marketing Dear Chris, Effective January 1, 2025, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”). In consideration of your appointment as Vice Pre |
|
| March 7, 2025 |
Effective January 1, 2025 James “Jim” Herman 430 Brentwood Oaks Drive Nashville, TN 37211 Re: Employment of James Herman, Vice President Trade and Distribution, Chief Compliance Officer Dear Jim, Effective January 1, 2025, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. |
|
| March 7, 2025 |
Fourth Amended and Restated Charter of Cumberland Pharmaceuticals Inc. Exhibit 3.1 I.THIRDFOURTH AMENDED AND RESTATED CHARTER OF CUMBERLAND PHARMACEUTICALS INC. Cumberland Pharmaceuticals Inc. (the “Company”), a corporation organized and existing under and by virtue of the Tennessee Business Corporation Act, as amended (the “Act”), does hereby certify: I.That the Company was incorporated upon the filing of its charter (the “Original Charter”) with the Secretary of St |
|
| March 7, 2025 |
Effective January 1, 2025 A.J. Kazimi 1600 West End Avenue, Suite 1300 Nashville, TN 37203 Re: Employment of A.J. Kazimi, Chief Executive Officer Dear A.J., Effective January 1, 2025, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”). In consideration of your appointment as Chief Executive Off |
|
| March 7, 2025 |
Insider Information Policy Insider Information For the purpose of this policy, Insider Information shall mean material, non-public information about Cumberland, or its current or prospective business partners, customers or vendors (“Cumberland or Related Parties”). |
|
| March 7, 2025 |
Effective January 1, 2025 Todd Anthony 702 Meeting Street Franklin, TN 37064 Re: Employment of Todd Anthony, Vice President Organizational Development Dear Todd, Effective January 1, 2025, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 of CUMBERLAND PHARMACEUTICALS INC. |
|
| March 7, 2025 |
Effective January 1, 2025 John Hamm 1659 Kirkwood Place Brentwood, TN 37207 Re: Employment of John Hamm, Vice President, Chief Financial Officer Dear John, Effective January 1, 2025, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. |
|
| March 4, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 4, 2025 (March 4, 2025) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inco |
|
| March 4, 2025 |
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth 2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval NASHVILLE, TENNESSEE (Tuesday, March 4, 2025) – Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, |
|
| February 19, 2025 |
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world’s second-largest market NASHVILLE, Tennessee, U. |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 19, 2025 (February 19, 2025) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| February 14, 2025 |
Up to $10,000,000 of Shares CUMBERLAND PHARMACEUTICALS INC. Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-276052 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 14, 2023) Up to $10,000,000 of Shares CUMBERLAND PHARMACEUTICALS INC. Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated December 14, 2023, filed as a part of our registration statement on Form S-3 (File No. 333-276052), as supplement |
|
| February 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 14, 2025 (February 14, 2025) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| February 11, 2025 |
EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, no par value, of Cumberland Pharmaceuticals Inc. |
|
| February 4, 2025 |
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease NASHVILLE, Tenn. |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 4, 2025 (February 4, 2025) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 9, 2024 (December 9, 2024) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| December 9, 2024 |
FDA APPROVES ACETADOTE® sNDA - New Dosing Regimen Simplifies Administration - FDA APPROVES ACETADOTE® sNDA - New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn. |
|
| November 12, 2024 |
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY NASHVILLE, Tenn. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 11, 2024 (November 6, 2024) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 7, 2024 |
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update –New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – –DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – NASHVILLE, TENNESSEE (Thursday, November 7, 2024) – Cumberland Pharmaceuticals Inc. |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 7, 2024 (November 7, 2024) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| November 6, 2024 |
New Study Compares Caldolor® (ibuprofen injection) to ketorolac –Real World Study Compared Over 150,000 Adult & Pediatric Patients – –Caldolor Associated with Fewer Adverse Drug Reactions – –Caldolor also Improved Healthcare Utilization – NASHVILLE, Tenn. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 6, 2024 (November 5, 2024) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 4, 2024 (November 4, 2024) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 6, 2024 |
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 NASHVILLE, TENNESSEE (Tuesday, August 6, 2024) – Cumberland Pharmaceuticals Inc. |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 6, 2024 (August 6, 2024) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 10, 2024 |
FIRST AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT LOAN AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT LOAN AGREEMENT (this “Amendment”) is entered into as of March 31, 2024, by and between CUMBERLAND PHARMACEUTICALS INC. |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 7, 2024 (May 7, 2024) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorpor |
|
| May 7, 2024 |
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update NASHVILLE, TENNESSEE (Tuesday, May 7, 2024) – Cumberland Pharmaceuticals Inc. |
|
| April 29, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 29, 2024 (April 29, 2024) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| March 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 20, 2024 Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorporation or or |
|
| March 20, 2024 |
Up to $5,800,000 of Shares CUMBERLAND PHARMACEUTICALS INC. Common Stock PROSPECTUS SUPPLEMENT (To Prospectus Dated December 14, 2023) Up to $5,800,000 of Shares CUMBERLAND PHARMACEUTICALS INC. |
|
| March 20, 2024 |
Exhibit 1.1 CUMBERLAND PHARMACEUTICALS INC. Common Stock (no par value per share) Sales Agreement March 20, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cumberland Pharmaceuticals Inc., a Tennessee corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”) as follows: 1.Issuance and Sale of Shares |
|
| March 13, 2024 |
Description of Cumberland Pharmaceutical's Common Stock Exhibit 4.11 DESCRIPTION OF THE REGISTRANT’S COMMON STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The common stock of Cumberland Pharmaceuticals, Inc. ( “we,” “our,” “us” or the “Company”) is registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our common stock is a summary and does not purport to be complete. |
|
| March 13, 2024 |
Exhibit 10.11 Effective January 1, 2024 A.J. Kazimi 1600 West End Avenue, Suite 1300 Nashville, TN 37203 Re: Employment of A.J. Kazimi, Chief Executive Officer Dear A.J., Effective January 1, 2024, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”). In consideration of your appointment as Chief |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 of CUMBERLAND PHARMACEUTICALS INC. |
|
| March 13, 2024 |
Exhibit 10.15 Effective January 1, 2024 John Hamm 1659 Kirkwood Place Brentwood, TN 37207 Re: Employment of John Hamm, Vice President, Chief Financial Officer Dear John, Effective January 1, 2024, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”). In consideration of your appointment as Vice P |
|
| March 13, 2024 |
Exhibit 10.13 Effective January 1, 2024 Todd Anthony 702 Meeting Street Franklin, TN 37064 Re: Employment of Todd Anthony, Vice President Organizational Development Dear Todd, Effective January 1, 2024, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”). In consideration of your appointment as |
|
| March 13, 2024 |
Exhibit 10.12 Effective January 1, 2024 James “Jim” Herman 430 Brentwood Oaks Drive Nashville, TN 37211 Re: Employment of James Herman, Executive Vice President National Accounts, Chief Compliance Officer Dear Jim, Effective January 1, 2024, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”). I |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement þ Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 13, 2024 |
Exhibit 10.14 Effective January 1, 2024 Chris Bitterman 605 Press Place, Apt. 107 Nashville, TN 37208 Re: Employment of Chris Bitterman, Vice President Sales & Marketing Dear Chris, Effective January 1, 2024, this agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”). In consideration of your appointme |
|
| March 13, 2024 |
Policy for the Recovery of Previously Awarded Incentive Compensation CUMBERLAND PHARMACEUTICALS INC. POLICY FOR THE RECOVERY OF PREVIOUSLY AWARDED INCENTIVE COMPENSATION A. OVERVIEW In accordance with the applicable rules of the Nasdaq Stock Market (the “Nasdaq Rules”), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), the Board of Directors (the “Board”) of Cumberland Pharmaceuticals Inc. (the “Compa |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 5, 2024 (March 5, 2024) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inco |
|
| March 5, 2024 |
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results 2023 highlights include expanded FDA approval and new study publications NASHVILLE, TENNESSEE (Tuesday, March 5, 2024) – Cumberland Pharmaceuticals Inc. |
|
| February 9, 2024 |
CPIX / Cumberland Pharmaceuticals Inc. / CUMBERLAND PHARMACEUTICALS INC - SC 13G Passive Investment SC 13G 1 schedule13g-2023.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* Cumberland Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| December 21, 2023 |
CUMBERLAND PHARMACEUTICALS, INC. 1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203 December 21, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Cumberland Pharmaceuticals, Inc. Registration Statement on Form S-3 File Number 333-276052 REQUEST FOR ACCELERATION OF EFFECTIVENESS Ladies and Gentlemen: Pursu |
|
| December 15, 2023 |
December 15, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 14, 2023 |
—Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Cumberland Pharmaceuticals Inc. |
|
| December 14, 2023 |
As filed with the Securities and Exchange Commission on December 14, 2023 Registration No. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 7, 2023 (November 7, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| November 7, 2023 |
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results NASHVILLE, TENNESSEE (Tuesday, November 7, 2023) - Cumberland Pharmaceuticals Inc. |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 13, 2023 (October 13, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| October 13, 2023 |
NEW VIBATIV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE NEW VIBATIV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE NASHVILLE, Tenn. |
|
| September 6, 2023 |
AMENDED AND RESTATED REVOLVING CREDIT LOAN AGREEMENT THIS AMENDED AND RESTATED REVOLVING CREDIT LOAN AGREEMENT (this “Loan Agreement”) is made and entered into as of September 5, 2023 by and between CUMBERLAND PHARMACEUTICALS INC. |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 5, 2023 (September 5, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 11, 2023 |
AMENDMENT NUMBER 3 TO THE CUMBERLAND PHARMACEUTICALS INC. AMENDED AND RESTATED 2007 LONG-TERM INCENTIVE COMPENSATION PLAN WHEREAS, Cumberland Pharmaceuticals Inc. (the “Company”), a corporation organized under the laws of Tennessee, originally adopted the Cumberland Pharmaceuticals Inc. 2007 Long-Term Incentive Compensation Plan on April 18, 2007, amended and restated by that certain amended and r |
|
| August 8, 2023 |
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 NASHVILLE, TENNESSEE (Tuesday, August 8, 2023) - Cumberland Pharmaceuticals Inc. |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 8, 2023 (August 8, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 26, 2023 (June 26, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inco |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 21, 2023 (June 16, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inco |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 7, 2023 (June 2, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorp |
|
| June 2, 2023 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 2, 2023 (May 30, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorp |
|
| May 24, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 24, 2023 (May 18, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorp |
|
| May 24, 2023 |
Exhibit 16.1 May 24, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on May 18, 2023, to be filed by our former client, Cumberland Pharmaceuticals Inc. We agree with the statements made in response to that Item insofar as they relate to our |
|
| May 16, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cumberland Pharmaceuticals Inc. |
|
| May 16, 2023 |
As filed with the Securities and Exchange Commission on May 16, 2023 As filed with the Securities and Exchange Commission on May 16, 2023 Registration No. |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 16, 2023 (May 15, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorp |
|
| May 16, 2023 |
CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS Caldolor® is the only injectable non-opioid approved for treating pain in infants NASHVILLE, TN (Monday, May 15, 2023) – Cumberland Pharmaceuticals Inc. |
|
| May 12, 2023 |
March 9, 2023 John Hamm 1659 Kirkwood Place Brentwood, TN 37216 Re: Employment of John Hamm Chief Financial Officer as by Cumberland Pharmaceuticals Inc. |
|
| May 12, 2023 |
March 9, 2023 James “Jim” Herman 430 Brentwood Oaks Dr Nashville, TN 37221 Re: Employment of Jim Herman Executive Vice President National Accounts & Chief Compliance Officer as by Cumberland Pharmaceuticals Inc. |
|
| May 12, 2023 |
March 9, 2023 Todd Anthony 702 Meeting Street Franklin, TN 37064 Re: Employment of Todd Anthony Vice President of Organizational Development as by Cumberland Pharmaceuticals Inc. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 12, 2023 |
March 9, 2023 Chris Bitterman 6440 Halcyon Garden Drive Alpharetta, GA 37090 Re: Employment of Chris Bitterman, Vice President of Sales and Marketing as by Cumberland Pharmaceuticals Inc. |
|
| May 12, 2023 |
March 9, 2023 Mr. A.J. Kazimi 1600 West End Avenue, Suite 1300 Nashville, TN 37203 Re: Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc. Dear AJ, Effective January 1, 2023, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”) In consideration of your app |
|
| May 9, 2023 |
Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update NASHVILLE, TENNESSEE (Tuesday, May 9, 2023) - Cumberland Pharmaceuticals Inc. |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 9, 2023 (May 9, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorpor |
|
| April 28, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 28, 2023 (April 25, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 14, 2023 (April 14, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 4, 2023 (March 30, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inc |
|
| March 15, 2023 |
March 9, 2023 Todd Anthony 702 Meeting Street Franklin, TN 37064 Re: Employment of Todd Anthony Vice President of Organizational Development as by Cumberland Pharmaceuticals Inc. |
|
| March 15, 2023 |
March 9, 2023 Mr. A.J. Kazimi 1600 West End Avenue, Suite 1300 Nashville, TN 37203 Re: Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc. Dear AJ, Effective January 1, 2023, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”) In consideration of your app |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 15, 2023 (March 9, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inc |
|
| March 15, 2023 |
March 9, 2023 John Hamm 1659 Kirkwood Place Brentwood, TN 37216 Re: Employment of John Hamm Chief Financial Officer as by Cumberland Pharmaceuticals Inc. |
|
| March 15, 2023 |
March 9, 2023 Chris Bitterman 6440 Halcyon Garden Drive Alpharetta, GA 37090 Re: Employment of Chris Bitterman, Vice President of Sales and Marketing as by Cumberland Pharmaceuticals Inc. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement þ Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 15, 2023 |
March 9, 2023 James “Jim” Herman 430 Brentwood Oaks Dr Nashville, TN 37221 Re: Employment of Jim Herman Executive Vice President National Accounts & Chief Compliance Officer as by Cumberland Pharmaceuticals Inc. |
|
| March 13, 2023 |
Exhibit 10.11 March 7, 2022 Mr. AJ Kazimi 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc. Dear AJ, Effective January 1, 2022, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”) In consideration |
|
| March 13, 2023 |
Description of Cumberland Pharmaceutical's Common Stock Exhibit 4.11 DESCRIPTION OF THE REGISTRANT’S COMMON STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The common stock of Cumberland Pharmaceuticals, Inc. ( “we,” “our,” “us” or the “Company”) is registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our common stock is a summary and does not purport to be complete. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 of CUMBERLAND PHARMACEUTICALS INC. |
|
| March 13, 2023 |
Exhibit 10.14 March 7, 2022 Mr. John Hamm 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of John Hamm as Senior Director of Finance & Accounting & Chief Financial Officer Cumberland Pharmaceuticals Inc. Dear John, Effective January 1, 2023, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceutica |
|
| March 13, 2023 |
Exhibit 10.15 March 7, 2022 Mr. James Herman 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of James Herman as Executive Vice President, National Accounts and Chief Compliance Officer Cumberland Pharmaceuticals Inc. Dear Jim, Effective January 1, 2023, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland P |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 7, 2023 (March 7, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inco |
|
| March 7, 2023 |
CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022 2022 highlights include its acquisition of Sancuso® and move to new headquarters NASHVILLE, TENNESSEE (Tuesday, March 7, 2023) - Cumberland Pharmaceuticals Inc. |
|
| February 10, 2023 |
CPIX / Cumberland Pharmaceuticals, Inc. / KAZIMI A J - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* Cumberland Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 17, 2023 (January 14, 2023) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 12, 2022 (December 6, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 14, 2022 |
NINTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT THIS NINTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this "Amendment") is entered into as of September 29, 2022 by and between CUMBERLAND PHARMACEUTICALS INC. |
|
| November 8, 2022 |
Cumberland Pharmaceuticals Reports 41% Revenue Growth Company Also Delivers Growing Cash Flow from Operations NASHVILLE, TENNESSEE (Tuesday, November 8, 2022) - Cumberland Pharmaceuticals Inc. |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 8, 2022 (November 8, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 12, 2022 |
EIGHTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT THIS EIGHTH AMENDMENT TO REVOL YING CREDIT LOAN AGREEMENT (this "Amendment") is entered into as of June 30, 2022 by and between CUMBERLAND PHARMACEUTICALS INC. |
|
| August 9, 2022 |
Cumberland Pharmaceuticals Reports 14% Revenue Growth Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, TENNESSEE (Tuesday, August 9, 2022) - Cumberland Pharmaceuticals Inc. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 9, 2022 (August 9, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 19, 2022 (July 15, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inco |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 3, 2022 (May 31, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorp |
|
| May 13, 2022 |
March 7, 2022 Mr. AJ Kazimi 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc. Dear AJ, Effective January 1, 2022, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the ?Company?) In consideration of your appoin |
|
| May 13, 2022 |
March 7, 2022 Mr. James Herman 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of James Herman as Executive Vice President, National Accounts and Chief Compliance Officer Cumberland Pharmaceuticals Inc. Dear John, Effective January 1, 2022, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceutical |
|
| May 13, 2022 |
March 7, 2022 Mr. John Hamm 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of John Hamm as Senior Director of Finance & Accounting & Chief Financial Officer Cumberland Pharmaceuticals Inc. Dear John, Effective January 1, 2022, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the ? |
|
| May 13, 2022 |
, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank. SEVENTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT THIS SEVENTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this "Amendment") is entered into as of March 31, 2022 by and between CUMBERLAND PHARMACEUTICALS INC. |
|
| May 13, 2022 |
March 7, 2022 Mr. Leo Pavliv 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of Leo Pavliv as Executive Vice President, Chief Development & Operations Officer by Cumberland Pharmaceuticals Inc. Dear Leo, Effective January 1, 2022, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (th |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 10, 2022 (May 10, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorp |
|
| May 10, 2022 |
Cumberland Pharmaceuticals Reports 6% Revenue Growth The Nashville-based specialty pharmaceutical company issues first quarter 2022 financial results and a company update NASHVILLE, TENNESSEE (Tuesday, May 10, 2022) - Cumberland Pharmaceuticals Inc. |
|
| May 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 3, 2022 (April 28, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incor |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 25, 2022 (April 19, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 22, 2022 (March 18, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| March 17, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The Unaudited Pro Forma Condensed Combined Financial Statements (referred to as the ?pro forma financial statements?) presented below are derived from the historical consolidated financial statements of Cumberland Pharmaceuticals, Inc. |
|
| March 17, 2022 |
Exhibit 99.2 SANCUSO? PRODUCT LINE OF KYOWA KIRIN, INC. Special Purpose Statement of Assets Acquired and Liabilities Assumed (Unaudited) September 30, 2021 2020 Assets acquired Current assets: Inventories $ 1,223,776 Prepaid expenses 369,413 Total current assets 1,593,189 Intangible assets, net 18,619,115 Net assets acquired $ 20,212,304 See accompanying notes to special purpose financial statemen |
|
| March 17, 2022 |
REPORT OF INDEPENDENT AUDITORS Exhibit 99.1 REPORT OF INDEPENDENT AUDITORS To the Management of Kyowa Kirin, Inc. We have audited the accompanying special purpose financial statements of the SANCUSO Product Line (?SANCUSO?) of Kyowa Kirin, Inc. (the ?Company?), which comprise the special purpose statement of assets acquired and liabilities assumed as of December 31, 2020, and the related special purpose statement of revenue and |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 17, 2022 (March 17, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of in |
|
| March 17, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 17, 2022 (March 17, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to ?240. |
|
| March 11, 2022 |
Exhibit 10.15 March 7, 2022 Mr. James Herman 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of James Herman as Executive Vice President, National Accounts and Chief Compliance Officer Cumberland Pharmaceuticals Inc. Dear John, Effective January 1, 2022, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland |
|
| March 11, 2022 |
Exhibit 10.14 March 7, 2022 Mr. John Hamm 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of John Hamm as Senior Director of Finance & Accounting & Chief Financial Officer Cumberland Pharmaceuticals Inc. Dear John, Effective January 1, 2022, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceutica |
|
| March 11, 2022 |
Exhibit 10.11 March 7, 2022 Mr. AJ Kazimi 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc. Dear AJ, Effective January 1, 2022, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the ?Company?) In consideration |
|
| March 11, 2022 |
Description of Cumberland Pharmaceutical's Common Stock Exhibit 4.11 DESCRIPTION OF THE REGISTRANT?S COMMON STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The common stock of Cumberland Pharmaceuticals, Inc. ( ?we,? ?our,? ?us? or the ?Company?) is registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our common stock is a summary and does not purport to be complete. |
|
| March 11, 2022 | ||
| March 11, 2022 |
EXECUTION VERSION OFFICE LEASE AGREEMENT between 1600 West End Avenue Partners, LLC, a Tennessee limited liability company Landlord and Cumberland Pharmaceuticals, Inc. |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 of CUMBERLAND PHARMACEUTICALS INC. |
|
| March 11, 2022 |
Exhibit 10.12 March 7, 2022 Mr. Martin E. Cearnal 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of Martine E. Cearnal as Executive Vice President, Chief Commercial Officer & President of Cumberland Pharmaceuticals Sales Operations by Cumberland Pharmaceuticals Inc. Dear Martin, Effective January 1, 2022, this letter agreement (the ?Agreement?) will evidence the terms and condi |
|
| March 11, 2022 |
Exhibit 10.13 March 7, 2022 Mr. Leo Pavliv 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of Leo Pavliv as Executive Vice President, Chief Development & Operations Officer by Cumberland Pharmaceuticals Inc. Dear Leo, Effective January 1, 2022, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceut |
|
| March 8, 2022 |
CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE 2021 highlights include agreement to acquire Sancuso? and FDA approval for Caldolor? administration prior to surgery NASHVILLE, TENNESSEE (Tuesday, March 8, 2022) - Cumberland Pharmaceuticals Inc. |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 8, 2022 (March 8, 2022) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inco |
|
| February 14, 2022 |
CPIX / Cumberland Pharmaceuticals, Inc. / KAZIMI A J - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* Cumberland Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Cumberland Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 6, 2022 |
ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this ?Agreement?) is effective as of the 31st day of December 2021 (the ?Effective Date?), by and among Kyowa Kirin, Inc. |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 January 6, 2022 (December 31, 2021) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. |
|
| January 6, 2022 |
CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO? FROM KYOWA KIRIN NORTH AMERICA Nashville-based pharmaceutical company will acquire U. |
|
| January 3, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 31, 2021 (December 31, 2021) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| December 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 December 27, 2021 Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. |
|
| December 27, 2021 |
Up to $19,000,000 of Shares CUMBERLAND PHARMACEUTICALS INC. Common Stock PROSPECTUS SUPPLEMENT (To Prospectus Dated January 8, 2021) Up to $19,000,000 of Shares CUMBERLAND PHARMACEUTICALS INC. |
|
| December 27, 2021 |
EX-1.2 2 ex12amendmentno1toatmsales.htm EX-1.2 AMENDMENT NO. 1 TO AT MARKET ISSUANCE SALES AGREEMENT December 27, 2021 B. Riley Securities, Inc. 299 Park Avenue, 7th Floor New York, NY 10171 Ladies and Gentlemen: Cumberland Pharmaceuticals Inc. (the “Company”) and B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.) (the “Agent,”) are parties to that certain At Market Issuance Sales Agreement d |
|
| December 1, 2021 |
CALDOLOR? NOW FDA APPROVED FOR PRE-OPERATIVE ADMINISTRATION Dosed prior to surgery, Caldolor? demonstrated significant reduction in pain intensity NASHVILLE, Tennessee (Monday, November 29, 2021) ? Cumberland Pharmaceuticals Inc. |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 30, 2021 (November 29, 2021) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 19, 2021 (November 15, 2021) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| November 19, 2021 |
Cumberland Pharmaceuticals Moving Corporate Headquarters to Broadwest FOR IMMEDIATE RELEASE November 16, 2021 Cumberland Pharmaceuticals Moving Corporate Headquarters to Broadwest NASHVILLE, Tennessee ? Broadwest is pleased to announce it has entered into an agreement with Cumberland Pharmaceuticals Inc. |
|
| November 12, 2021 | ||
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 9, 2021 |
CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, Tennessee (Tuesday, November 9, 2021) - Cumberland Pharmaceuticals Inc. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 9, 2021 (November 9, 2021) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| November 1, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 1, 2021 (October 28, 2021) Date of Report (date of earliest event reported) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 10, 2021 |
CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS & COMPANY UPDATE Year-to-date net revenues up 9. |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a2021q28k-er.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 10, 2021 (August 10, 2021) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (Sta |
|
| June 14, 2021 |
Entry into a Material Definitive Agreement 8-K 1 ppploanforgiven.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 14, 2021 (June 11, 2021) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (Stat |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 14, 2021 (May 14, 2021) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incor |
|
| May 14, 2021 |
May 14, 2021 John Hamm 1659 Kirkwood Place Brentwood, TN 37027 Re: Employment of John Hamm as Senior Director Finance & Accounting and Chief Financial Officer by Cumberland Pharmaceuticals Inc. |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 11, 2021 (May 11, 2021) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incor |
|
| May 11, 2021 |
CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, Tennessee (Tuesday, May 11, 2021) - Cumberland Pharmaceuticals Inc. |
|
| April 30, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 30, 2021 (April 27, 2021) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of i |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to ?240. |
|
| March 12, 2021 |
Exhibit 10.15 March 8, 2021 Mr. James L. Herman 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of James L. Herman as Senior Vice President, National Accounts and Chief Compliance Officer by Cumberland Pharmaceuticals Inc. Dear Jim: Effective January 1, 2021, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumber |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 of CUMBERLAND PHARMACEUTICALS INC. |
|
| March 12, 2021 |
Exhibit 10.13 March 8, 2021 Mr. Leo Pavliv 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of Leo Pavliv as Executive Vice President, Operations and Chief Development Officer by Cumberland Pharmaceuticals Inc. Dear Leo, Effective January 1, 2021, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmace |
|
| March 12, 2021 |
EX-10.14 6 a2020-xex1014michaelbonner.htm EX-10.14 Exhibit 10.14 March 8, 2021 Mr. Michael Bonner 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of Michael Bonner as Senior Director, Finance & Accounting; Chief Financial Officer by Cumberland Pharmaceuticals Inc. Dear Michael: Effective January 1, 2021, this letter agreement (the “Agreement”) will evidence the terms and conditi |
|
| March 12, 2021 |
Exhibit 10.12 March 8, 2021 Mr. Martin E. Cearnal 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of Martin E. Cearnal as Executive Vice President, Chief Commercial Officer by Cumberland Pharmaceuticals Inc. Dear Martin: Effective January 1, 2021, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmac |
|
| March 12, 2021 |
Description of Cumberland Pharmaceutical's Common Stock Exhibit 4.11 DESCRIPTION OF THE REGISTRANT?S COMMON STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The common stock of Cumberland Pharmaceuticals, Inc. ( ?we,? ?our,? ?us? or the ?Company?) is registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our common stock is a summary and does not purport to be complete. |
|
| March 12, 2021 |
Exhibit 10.11 March 8, 2021 Mr. A.J. Kazimi 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of A.J. Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc. Dear A.J.: Effective January 1, 2021, this letter agreement (the ?Agreement?) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the ?Company?) In consider |
|
| March 9, 2021 |
CUMBERLAND PHARMACEUTICALS REPORTS 9% REVENUE GROWTH IN 2020 CUMBERLAND PHARMACEUTICALS REPORTS 9% REVENUE GROWTH IN 2020 NASHVILLE, TENNESSEE (Tuesday, March 9, 2021) - Cumberland Pharmaceuticals Inc. |
|
| March 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 9, 2021 (March 9, 2021) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inc |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Cumberland Pharmaceuticals Inc. (Name of Issuer) Common stock, no par value (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Cumberland Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* Cumberland Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 6, 2021 |
2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 January 6, 2021 VIA EDGAR Mr. |
|
| December 11, 2020 |
As filed with the Securities and Exchange Commission on December 11, 2020 Registration No. |
|
| December 10, 2020 |
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Index Page Number PART II 2 Item 6: Selected Financial Data 2 Item 7: Management?s Discussion and Analysis of Financial Condition and Results of Operations 4 Item 8: Financial Statements and Supplementary Data 19 Report of Independent Registered Public Accounting Firm F-1 Consolidated Balance Sheets F-2 Consolidated Statements of Operations and Comp |
|
| December 10, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 10, 2020 (December 10, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdictio |
|
| November 13, 2020 |
THIRD AMENDMENT TO REVOLVING CREDIT NOTE AND FOURTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT THIS THIRD AMENDMENT TO REVOLVING CREDIT NOTE AND FOURTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this ?Amendment?) is entered into as of October 7, 2020, by and between CUMBERLAND PHARMACEUTICALS INC. |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 10, 2020 |
CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, Tennessee (Tuesday, November 10, 2020) - Cumberland Pharmaceuticals Inc. |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 10, 2020 (November 10, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdictio |
|
| October 16, 2020 |
October 16, 2020 VIA EDGAR CORRESPONDENCE Ms. Jeanne Baker Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Cumberland Pharmaceuticals Inc. Form 10-K for the Fiscal year Ended December 31, 2019 and Form 8-K filed May 20, 2020 File No. 001-33637 Dear Ms. Baker: This letter is provided on behalf of Cumberland Pharmaceutica |
|
| October 9, 2020 |
Entry into a Material Definitive Agreement - 8-K FOURTH AMENDMENT TO REVOLVING LINE OF CREDIT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 9, 2020 (October 7, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of |
|
| September 18, 2020 |
September 18, 2020 VIA EDGAR CORRESPONDENCE Ms. Jeanne Baker Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Cumberland Pharmaceuticals Inc. Form 10-K for the Fiscal year Ended December 31, 2019 and Form 8-K filed May 20, 2020 File No. 001-33637 Dear Ms. Baker: This letter is provided on behalf of Cumberland Pharmaceuti |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 14, 2020 |
exhibit103-form147716ba DocuSign Envelope ID: E7C3AEA6-A740-4BF5-BA8D-743B58722B0E U. |
|
| August 14, 2020 |
AMENDMENT NUMBER 2 TO THE CUMBERLAND PHARMACEUTICALS INC. AMENDED AND RESTATED 2007 DIRECTORS’ INCENTIVE PLAN WHEREAS, Cumberland Pharmaceuticals Inc. (the “Company”), a corporation organized under the laws of Tennessee, originally adopted the Cumberland Pharmaceuticals Inc. 2007 Directors’ Incentive Plan on April 18, 2007, as amended and restated effective as of April 17, 2012 (the “Plan”). WHERE |
|
| August 14, 2020 |
AMENDMENT NUMBER 2 TO THE CUMBERLAND PHARMACEUTICALS INC. AMENDED AND RESTATED 2007 LONG-TERM INCENTIVE COMPENSATION PLAN WHEREAS, Cumberland Pharmaceuticals Inc. (the “Company”), a corporation organized under the laws of Tennessee, originally adopted the Cumberland Pharmaceuticals Inc. 2007 Long-Term Incentive Compensation Plan on April 18, 2007, amended and restated by that certain amended and r |
|
| August 11, 2020 |
CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, TN (Tuesday, August 11, 2020) - Cumberland Pharmaceuticals Inc. |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 11, 2020 (August 11, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of |
|
| July 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| July 22, 2020 |
July 22, 2020 VIA EDGAR CORRESPONDENCE Ms. Jeanne Baker Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Cumberland Pharmaceuticals Inc. Form 10-K for the Fiscal year Ended December 31, 2019 and Form 8-K filed May 20, 2020 File No. 001-33637 Dear Ms. Baker: This letter is provided on behalf of Cumberland Pharmaceuticals |
|
| May 29, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 29, 2020 (May 26, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incor |
|
| May 29, 2020 |
NEW PUBLICATION REVEALS REAL-WORLD USAGE OF VIBATIV® IN PATIENTS WITH BACTEREMIA OR ENDOCARDITIS NEW PUBLICATION REVEALS REAL-WORLD USAGE OF VIBATIV® IN PATIENTS WITH BACTEREMIA OR ENDOCARDITIS NASHVILLE, Tenn. |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 20, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 20, 2020 (May 20, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incor |
|
| May 20, 2020 |
CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, TN (Wednesday, May 20, 2020) - Cumberland Pharmaceuticals Inc. |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 8, 2020 (May 5, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorpo |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 8, 2020 (May 8, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of incorpo |
|
| May 1, 2020 |
Letter to the Securities and Exchange Commission from BDO USA, LLP [BDO Letterhead] Exhibit 16.1 May 1, 2020 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 29, 2020, to be filed by our former client, Cumberland Pharmaceuticals Inc. We agree with the statements made in response to that Item insofar as t |
|
| May 1, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 1, 2020 (April 29, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of inco |
|
| April 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 21, 2020 (April 20, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of i |
|
| March 20, 2020 |
Exhibit 10.12 March 16, 2020 Mr. Martin E. Cearnal 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of Martin E. Cearnal as Executive Vice President, Chief Commercial Officer by Cumberland Pharmaceuticals Inc. Dear Martin: Effective January 1, 2020, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharma |
|
| March 20, 2020 |
Exhibit 10.13 March 16, 2020 Mr. Leo Pavliv 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of Leo Pavliv as Executive Vice President, Operations and Chief Development Officer by Cumberland Pharmaceuticals Inc. Dear Leo, Effective January 1, 2020, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmac |
|
| March 20, 2020 |
Exhibit 10.15 March 16, 2020 Mr. James L. Herman 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of James L. Herman as Senior Vice President, National Accounts and Chief Compliance Officer by Cumberland Pharmaceuticals Inc. Dear Jim: Effective January 1, 2020, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumbe |
|
| March 20, 2020 |
Exhibit 10.14 March 16, 2020 Mr. Michael Bonner 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of Michael Bonner as Senior Director, Finance & Accounting; Chief Financial Officer by Cumberland Pharmaceuticals Inc. Dear Michael: Effective January 1, 2020, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland |
|
| March 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 of CUMBERLAND PHARMACEUTICALS INC. |
|
| March 20, 2020 |
CPIX / Cumberland Pharmaceuticals Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 20, 2020 |
Exhibit 10.11 March 16, 2020 Mr. A.J. Kazimi 2525 West End Avenue, Suite 950 Nashville, TN 37203 Re: Employment of A.J. Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc. Dear A.J.: Effective January 1, 2020, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”) In conside |
|
| March 18, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 18, 2020 (March 18, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of i |
|
| March 18, 2020 |
CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR THE FULL YEAR 2019 - Received FDA approval for RediTrexTM - Completed Caldolor® pediatric study in newborns - Initiated new ifetroban clinical program NASHVILLE, TENNESSEE (Wednesday, March 18, 2020) - Cumberland Pharmaceuticals Inc. |
|
| February 13, 2020 |
CPIX / Cumberland Pharmaceuticals Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cumberland Pharmaceuticals Inc. (Name of Issuer) Common stock, no par value (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* CUMBERLAND PHARMACEUTICALS (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 7, 2020 |
CPIX / Cumberland Pharmaceuticals Inc. / CUMBERLAND PHARMACEUTICALS INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* Cumberland Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 230770109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 10, 2020 (January 7, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction o |
|
| January 10, 2020 |
CUMBERLAND PHARMACEUTICALS ANNOUNCES THE NATIONAL LAUNCH OF A NEW CALDOLOR READY-TO-USE PRODUCT Caldolor® now available in a pre-mixed, ready-to-use bag. |
|
| January 3, 2020 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 3, 2020 (January 1, 2020) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction of |
|
| January 3, 2020 |
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Unaudited Pro Forma Condensed Consolidated Financial Information Under the final terms of the amended Agreement, the Company returned the Product rights to Clinigen on December 31, 2019. The return of these Products is collectively referred to as the "Ethyol and Totect Exit" throughout the unaudited pro forma condensed consolidated financial stateme |
|
| December 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 6, 2019 (December 2, 2019) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| December 6, 2019 |
Cumberland Pharmaceuticals Receives FDA Approval for RediTrexTM Product Line Cumberland Pharmaceuticals Receives FDA Approval for RediTrexTM Product Line NASHVILLE, TENNESSEE (Monday, December 2, 2019) - Cumberland Pharmaceuticals Inc. |
|
| November 29, 2019 |
NEW STUDY REVEALS REAL-WORLD USAGE OF VIBATIV® IN A VARIETY OF INFECTIONS NEW STUDY REVEALS REAL-WORLD USAGE OF VIBATIV® IN A VARIETY OF INFECTIONS NASHVILLE, Tenn. |
|
| November 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 29, 2019 (November 25, 2019) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdictio |
|
| November 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 12, 2019 |
CUMBERLAND PHARMACEUTICALS REPORTS 22% REVENUE GROWTH IN THE THIRD QUARTER CUMBERLAND PHARMACEUTICALS REPORTS 22% REVENUE GROWTH IN THE THIRD QUARTER NASHVILLE, TN (Tuesday, November 12, 2019) - Cumberland Pharmaceuticals Inc. |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 12, 2019 (November 12, 2019) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdictio |
|
| October 18, 2019 |
NEW STUDY REVEALS SUPERIORITY OF VIBATIV® OVER VANCOMYCIN IN SELECT PATIENTS WITH BACTERIAL PNEUMONIA NASHVILLE, Tenn. |
|
| October 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 18, 2019 (October 15, 2019) CUMBERLAND PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Tennessee 001-33637 62-1765329 (State or other jurisdiction |
|
| September 27, 2019 |
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA ORPHAN DRUG GRANT AWARD FOR NEW PHASE II CLINICAL PROGRAM CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA ORPHAN DRUG GRANT AWARD FOR NEW PHASE II CLINICAL PROGRAM NASHVILLE, TENNESSEE (Tuesday, September 24, 2019) - Cumberland Pharmaceuticals Inc. |
